Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 9, 2013, Pages 1956-1961

  Anguille, Sébastien ^a,b   Lion, Eva ^a   Van Den Bergh, Johan ^a   Van Acker, Heleen H ^a   Willemen, Yannick ^a,b   Smits, Evelien L ^a,b   Van Tendeloo, Viggo F ^a   Berneman, Zwi N ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cancer vaccination; Dendritic cells; Interleukin 15 dendritic cells; Killer dendritic cells; Natural killer cells

Indexed keywords

DENDRITIC CELL VACCINE; INTERLEUKIN 15; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL MIGRATION; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG EFFICACY; DRUG POTENCY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; INNATE IMMUNITY; MELANOMA; MOLECULAR INTERACTION; NONHUMAN; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR CELL DESTRUCTION;

CANCER VACCINATION; DENDRITIC CELLS; INTERLEUKIN-15 DENDRITIC CELLS; KILLER DENDRITIC CELLS; NATURAL KILLER CELLS;

CANCER VACCINES; DENDRITIC CELLS; DRUG DISCOVERY; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-15; NEOPLASMS;

EID: 84884609956     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25373     Document Type: Review

References (29)

1. Shurin MR. Cancer as an immune-mediated disease. ImmunoTargets and Therapy 2012; 1:1-6; http://dx.doi.org/10.2147/ITT.S29834
2. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer 2004; 4:401-11; PMID:15122211; http://dx.doi.org/10.1038/nrc1359
3. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10:475-80; PMID:15122249; http://dx.doi.org/10.1038/nm1039
4. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258
5. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2:52-8; PMID:8564842; http://dx.doi.org/10.1038/ nm0196-52
6. Anguille S, Lion E, Smits E, Berneman ZN, van Tendeloo VF. Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers. Hum Vaccin 2011; 7:579-84; PMID:21422813; http://dx.doi.org/10.4161/hv.7.5.14652
7. Anguille S, Willemen Y, Lion E, Smits EL, Berneman ZN. Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy 2012; 14:647-56; PMID:22686130
8. Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K, et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 2007; 56:1513-37; PMID:17503040; http://dx.doi.org/10.1007/s00262-007-0334-z
9. Anguille S, Smits EL, Cools N, Goossens H, Berneman ZN, Van Tendeloo VF. Short-Term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med 2009; 7:109; PMID:20021667; http://dx.doi.org/10.1186/1479-5876-7-109
10. Mohamadzadeh M, Berard F, Essert G, Chalouni C, Pulendran B, Davoust J, et al. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med 2001; 194:1013-20; PMID:11581322; http://dx.doi.org/10.1084/jem.194.7.1013
11. Saikh KU, Khan AS, Kissner T, Ulrich RG. IL-15-induced conversion of monocytes to mature dendritic cells. Clin Exp Immunol 2001; 126:447-55; PMID:11737061; http://dx.doi.org/10.1046/j.1365-2249.2001.01672.x
12. Pulendran B, Dillon S, Joseph C, Curiel T, Banchereau J, Mohamadzadeh M. Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent CD8+ Tc1 responses in vivo. Eur J Immunol 2004; 34:66-73; PMID:14971031; http://dx.doi.org/10.1002/eji.200324567
13. Feili-Hariri M, Falkner DH, Morel PA. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy. J Leukoc Biol 2005; 78:656-64; PMID:15961574; http://dx.doi.org/10.1189/jlb.1104631
14. Dubsky P, Saito H, Leogier M, Dantin C, Connolly JE, Banchereau J, et al. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol 2007; 37:1678-90; PMID:17492620; http://dx.doi.org/10.1002/eji.200636329
15. Hardy MY, Kassianos AJ, Vulink A, Wilkinson R, Jongbloed SL, Hart DN, et al. NK cells enhance the induction of CTL responses by IL-15 monocyte-derived dendritic cells. Immunol Cell Biol 2009; 87:606-14; PMID:19546878; http://dx.doi.org/10.1038/icb.2009.44
16. Harris KM. Monocytes differentiated with GM-CSF and IL-15 initiate Th17 and Th1 responses that are contact-dependent and mediated by IL-15. J Leukoc Biol 2011; 90:727-34; PMID:21724805; http://dx.doi.org/10.1189/jlb.0311132
17. Hanke NT. Molecular Regulation of the Tumor Killing Activity of Dendritic Cells. PhD dissertation 2012; The University of Arizona, Tucson, AZ USA.
18. Anguille S, Lion E, Tel J, de Vries IJ, Couderé K, Fromm PD, et al. Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS One 2012; 7:e51851; PMID:23284789; http://dx.doi.org/10.1371/journal.pone.0051851
19. Celli S, Day M, Müller AJ, Molina-Paris C, Lythe G, Bousso P. How many dendritic cells are required to initiate a T-cell response? Blood 2012; 120:3945-8; PMID:22995897; http://dx.doi.org/10.1182/blood-2012-01-408260
20. Anguille S, Van Tendeloo VF, Berneman ZN. Leukemia-Associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 2012; 26:2186-96; PMID:22652755; http://dx.doi.org/10.1038/leu.2012.145
21. Smits EL, Anguille S, Cools N, Berneman ZN, Van Tendeloo VF. Dendritic cell-based cancer gene therapy. Hum Gene Ther 2009; 20:1106-18; PMID:19656053; http://dx.doi.org/10.1089/hum.2009.145
22. Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-Targeted dendritic cell vaccination. Proc Natl Acad Sci U S A 2010; 107:13824-9; PMID:20631300; http://dx.doi.org/10.1073/ pnas.1008051107
23. Bürdek M, Spranger S, Wilde S, Frankenberger B, Schendel DJ, Geiger C. Three-day dendritic cells for vaccine development: antigen uptake, processing and presentation. J Transl Med 2010; 8:90; PMID:20920165; http://dx.doi.org/10. 1186/1479-5876-8-90
24. Romano E, Cotari JW, Barreira da Silva R, Betts BC, Chung DJ, Avogadri F, et al. Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1. Blood 2012; 119:5182-90; PMID:22510877; http://dx.doi.org/10.1182/ blood-2011-09-382200
25. Roothans D, Smits E, Lion E, Tel J, Anguille S. CD56 marks human dendritic cell subsets with cytotoxic potential. Oncoimmunology 2013; 2:e23037; PMID:23524451; http://dx.doi.org/10.4161/onci.23037
26. Larmonier N, Fraszczak J, Lakomy D, Bonnotte B, Katsanis E. Killer dendritic cells and their potential for cancer immunotherapy. Cancer Immunol Immunother 2010; 59:1-11; PMID:19618185; http://dx.doi.org/10.1007/s00262-009- 0736-1
27. Lion E, Smits EL, Berneman ZN, Van Tendeloo VF. NK cells: key to success of DC-based cancer vaccines? Oncologist 2012; 17:1256-70; PMID:22907975; http://dx.doi.org/10.1634/theoncologist.2011-0122
28. Lion E, Willemen Y, Berneman ZN, Van Tendeloo VF, Smits EL. Natural killer cell immune escape in acute myeloid leukemia. Leukemia 2012; 26:2019-26; PMID:22446501; http://dx.doi.org/10.1038/leu.2012.87
29. Hardy MY. Manipulation of human dendritic cell subsets and the design of optimal preparations for tumour immunotherapy. PhD dissertation 2008; The University of Queensland, QLD, Australia.